Peers of Inhibikase Therapeutics Inc (IKT)
Side-by-side comparison
Health Care · Biotechnology
Market capitalization divided by trailing twelve-month revenue. A valuation metric often used when earnings are negative or not meaningful.
Latest P/S Ratio
105.59x
As of Sep 27, 2024
Beyond P/S Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | P/S Ratio |
|---|---|
| Sep 27, 2024 | 105.59x |
| Sep 26, 2024 | 103.79x |
| Sep 25, 2024 | 101.98x |
| Sep 24, 2024 | 103.79x |
| Sep 23, 2024 | 105.59x |
| Sep 20, 2024 | 108.30x |
| Sep 19, 2024 | 104.69x |
| Sep 18, 2024 | 105.59x |
P/S Ratio = Market Capitalization / Revenue (TTM)
P/S ignores profitability and capital structure, making it a simple but blunt valuation tool.
Read the general P/S Ratio definition, formula, and analyst usage guide.
P/S Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison